Technology
Health
Pharmaceutical

Oramed Pharmaceuticals

$3.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-0.62%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ORMP and other stocks, options, ETFs, and crypto commission-free!

About

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Read More The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.

Employees
13
Headquarters
Jerusalem, Jerusalem
Founded
2002
Market Cap
55.96M
Price-Earnings Ratio
Dividend Yield
Average Volume
33.53K
High Today
$3.25
Low Today
$3.19
Open Price
$3.25
Volume
716.00
52 Week High
$8.59
52 Week Low
$2.78

Collections

Technology
Health
Pharmaceutical
Research And Development
Asia (Non-China)
Asia

News

Simply Wall StFeb 27

Do Insiders Own Shares In Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)?

The big shareholder groups in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. So it’s nice to see some insider ownership, because it may suggest that management is owner-oriented. Oramed Pharmaceuticals is a sm...

43
MarketBeatFeb 15

Stock Price, News, & Analysis for Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security...

29
PR NewswireFeb 13

Frost & Sullivan Publishes Q1 2019 Update on Oramed Pharmaceuticals Inc.

TEL AVIV, Israel, Feb 13, 2019 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise investor awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure of investors from Israel and abroad.

2

Earnings

-$0.30
-$0.25
-$0.20
-$0.15
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.24 per share
Actual
Expected Mar 26, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.